Ocular Therapeutix (OCUL) Expected to Announce Earnings on Monday

Ocular Therapeutix (NASDAQ:OCUL) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Ocular Therapeutix to post earnings of ($0.33) per share and revenue of $16.1280 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 7:00 AM ET.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The company had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. During the same period in the prior year, the business earned ($0.29) earnings per share. Ocular Therapeutix’s quarterly revenue was down 22.4% on a year-over-year basis. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $7.78 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The firm has a 50 day simple moving average of $10.76 and a 200 day simple moving average of $11.67. Ocular Therapeutix has a fifty-two week low of $5.78 and a fifty-two week high of $16.44. The firm has a market cap of $1.69 billion, a P/E ratio of -5.40 and a beta of 0.90.

Insider Activity at Ocular Therapeutix

In other news, COO Donald Notman sold 11,446 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $103,471.84. Following the completion of the transaction, the chief operating officer owned 366,356 shares in the company, valued at $3,311,858.24. This represents a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pravin Dugel sold 124,882 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the sale, the insider owned 3,033,078 shares in the company, valued at approximately $27,419,025.12. The trade was a 3.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 166,029 shares of company stock worth $1,498,430. Corporate insiders own 2.30% of the company’s stock.

Institutional Trading of Ocular Therapeutix

Institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC grew its holdings in shares of Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix in the 4th quarter valued at approximately $61,000. State of Wyoming bought a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $78,000. Quarry LP bought a new position in shares of Ocular Therapeutix during the 3rd quarter worth approximately $80,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Ocular Therapeutix by 1,077.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 9,217 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 8,434 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on OCUL shares. Needham & Company LLC lowered their target price on Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Friday. Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Chardan Capital reiterated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.